Inhibikase Therapeutics Inc Cash Flow Reinvestment Rate

Latest as of September 2020: 0.00x

Inhibikase Therapeutics Inc cash flow reinvestment rate. Inhibikase Therapeutics Inc (IKT) has a Cash Flow Reinvestment Rate of 0.00x as of September 2020, reinvesting $0.00 (capex $0.00 ) from operating cash flow of $75.52K. Explore Inhibikase Therapeutics Inc debt service capacity to assess how comfortably operating cash covers total debt obligations.

Reinvestment Rate

0.00x

(Capex + Investments) / Operating CF

Total Reinvested

$0.00

Capex + Investments

Operating Cash Flow

$75.52K

USD

Capital Expenditures

$0.00

USD

Cash Flow Reinvestment Rate of Inhibikase Therapeutics Inc (2018–2018)

Cash flow reinvestment rate of Inhibikase Therapeutics Inc from 2018 to 2018. Historical reinvestment intensity for Inhibikase Therapeutics Inc across 1 annual periods. Also explore IKT year-over-year net asset growth to track the company's year-over-year net asset growth rate.

Inhibikase Therapeutics Inc Cash Flow Reinvestment Rate by Year (2018–2018)

Inhibikase Therapeutics Inc cash flow reinvestment rate by year from 2018 to 2018. Year-by-year capital reinvestment analysis for Inhibikase Therapeutics Inc. For the full cash flow conversion analysis, see Inhibikase Therapeutics Inc operating cash flow efficiency.

Year	Reinvestment Rate	Total Reinvested (USD)	Operating CF	Capex	YoY Change
2018	0.12x	$87.10K	$714.99K	$0.00	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow